Literature DB >> 22009723

Dietary phosphate restriction normalizes biochemical and skeletal abnormalities in a murine model of tumoral calcinosis.

Shoji Ichikawa1, Anthony M Austin, Amie K Gray, Matthew R Allen, Michael J Econs.   

Abstract

Mutations in the GALNT3 gene cause tumoral calcinosis characterized by ectopic calcifications due to persistent hyperphosphatemia. We recently developed Galnt3 knockout mice in a mixed background, which had hyperphosphatemia with increased bone mineral density (BMD) and infertility in males. To test the effect of dietary phosphate intake on their phenotype, Galnt3 knockout mice were generated in the C57BL/6J strain and fed various phosphate diets: 0.1% (low), 0.3% (low normal), 0.6% (normal), and 1.65% (high). Sera were analyzed for calcium, phosphorus, alkaline phosphatase, creatinine, blood urine nitrogen, 1,25-dihydroxyvitamin D, osteocalcin, tartrate-resistant acid phosphatase 5b, and fibroblast growth factor 23 (Fgf23). Femurs were evaluated by dual-energy x-ray absorptiometry, dynamic histomorphometry, and/or microcomputed tomography. Galnt3 knockout mice in C57BL/6J had the same biochemical phenotype observed in our previous study: hyperphosphatemia, inappropriately normal 1,25-dihydroxyvitamin D level, decreased alkaline phosphatase activity, and low intact Fgf23 concentration but high Fgf23 fragments. Skeletal analyses of their femurs revealed significantly high BMD with increased cortical bone area and trabecular bone volume. On all four phosphate diets, Galnt3 knockout mice had consistently higher phosphorus levels and lower alkaline phosphatase and intact Fgf23 concentrations than littermate controls. The low-phosphate diet normalized serum phosphorus, alkaline phosphatase, and areal BMD but failed to correct male infertility in Galnt3 knockout mice. The high-phosphate diet did not increase serum phosphorus concentration in either mutant or control mice due to a compensatory increase in circulating intact Fgf23 levels. In conclusion, dietary phosphate restriction normalizes biochemical and skeletal phenotypes of Galnt3 knockout mice and, thus, can be an effective therapy for tumoral calcinosis.

Entities:  

Mesh:

Substances:

Year:  2011        PMID: 22009723      PMCID: PMC3230057          DOI: 10.1210/en.2011-1137

Source DB:  PubMed          Journal:  Endocrinology        ISSN: 0013-7227            Impact factor:   4.736


  42 in total

1.  Polypeptide GalNAc-transferase T3 and familial tumoral calcinosis. Secretion of fibroblast growth factor 23 requires O-glycosylation.

Authors:  Kentaro Kato; Charlotte Jeanneau; Mads Agervig Tarp; Anna Benet-Pagès; Bettina Lorenz-Depiereux; Eric Paul Bennett; Ulla Mandel; Tim M Strom; Henrik Clausen
Journal:  J Biol Chem       Date:  2006-04-25       Impact factor: 5.157

2.  Hyperphosphatemia associated with cortical hyperostosis and tumoral calcinosis.

Authors:  M P Wilson; C B Lindsley; B A Warady; J A Johnson
Journal:  J Pediatr       Date:  1989-06       Impact factor: 4.406

3.  A novel homozygous missense mutation in FGF23 causes Familial Tumoral Calcinosis associated with disseminated visceral calcification.

Authors:  Ilana Chefetz; Raoul Heller; Assimina Galli-Tsinopoulou; Gabriele Richard; Bernd Wollnik; Margarita Indelman; Friederike Koerber; Orit Topaz; Reuven Bergman; Eli Sprecher; Eckhard Schoenau
Journal:  Hum Genet       Date:  2005-11-15       Impact factor: 4.132

4.  Tumoral calcinosis presenting with eyelid calcifications due to novel missense mutations in the glycosyl transferase domain of the GALNT3 gene.

Authors:  Shoji Ichikawa; Erik A Imel; Andrea H Sorenson; Rebecca Severe; Paul Knudson; Gerald J Harris; Joseph L Shaker; Michael J Econs
Journal:  J Clin Endocrinol Metab       Date:  2006-08-29       Impact factor: 5.958

5.  Klotho converts canonical FGF receptor into a specific receptor for FGF23.

Authors:  Itaru Urakawa; Yuji Yamazaki; Takashi Shimada; Kousuke Iijima; Hisashi Hasegawa; Katsuya Okawa; Toshiro Fujita; Seiji Fukumoto; Takeyoshi Yamashita
Journal:  Nature       Date:  2006-10-29       Impact factor: 49.962

6.  Novel GALNT3 mutations causing hyperostosis-hyperphosphatemia syndrome result in low intact fibroblast growth factor 23 concentrations.

Authors:  Shoji Ichikawa; Vincent Guigonis; Erik A Imel; Mélanie Courouble; Sophie Heissat; John D Henley; Andrea H Sorenson; Barbara Petit; Anne Lienhardt; Michael J Econs
Journal:  J Clin Endocrinol Metab       Date:  2007-02-20       Impact factor: 5.958

7.  Hyperostosis-hyperphosphatemia syndrome: a congenital disorder of O-glycosylation associated with augmented processing of fibroblast growth factor 23.

Authors:  Yaacov Frishberg; Nobuaki Ito; Choni Rinat; Yuji Yamazaki; Sofia Feinstein; Itaru Urakawa; Paulina Navon-Elkan; Rachel Becker-Cohen; Takeyoshi Yamashita; Kaori Araya; Takashi Igarashi; Toshiro Fujita; Seiji Fukumoto
Journal:  J Bone Miner Res       Date:  2007-02       Impact factor: 6.741

8.  The role of mutant UDP-N-acetyl-alpha-D-galactosamine-polypeptide N-acetylgalactosaminyltransferase 3 in regulating serum intact fibroblast growth factor 23 and matrix extracellular phosphoglycoprotein in heritable tumoral calcinosis.

Authors:  Holly J Garringer; Corinne Fisher; Tobias E Larsson; Siobhan I Davis; Daniel L Koller; Michael J Cullen; Mohamad S Draman; Niamh Conlon; Alka Jain; Neal S Fedarko; Bhaskar Dasgupta; Kenneth E White
Journal:  J Clin Endocrinol Metab       Date:  2006-07-25       Impact factor: 5.958

9.  A homozygous missense mutation in human KLOTHO causes severe tumoral calcinosis.

Authors:  Shoji Ichikawa; Erik A Imel; Mary L Kreiter; Xijie Yu; Donald S Mackenzie; Andrea H Sorenson; Regina Goetz; Moosa Mohammadi; Kenneth E White; Michael J Econs
Journal:  J Clin Invest       Date:  2007-09       Impact factor: 14.808

10.  Two novel GALNT3 mutations in familial tumoral calcinosis.

Authors:  Holly J Garringer; Seyed Mohammad Javad Mortazavi; Fatemehsadat Esteghamat; Mahdi Malekpour; Harika Boztepe; Refik Tanakol; Siobhan I Davis; Kenneth E White
Journal:  Am J Med Genet A       Date:  2007-10-15       Impact factor: 2.802

View more
  10 in total

1.  Acute tumoral calcinosis due to severe hyperphosphatemia in a maintenance hemodialysis patient.

Authors:  Keizo Nishime; Hiroki Takahashi
Journal:  CEN Case Rep       Date:  2016-06-24

2.  Galnt3 deficiency disrupts acrosome formation and leads to oligoasthenoteratozoospermia.

Authors:  Toshihiro Miyazaki; Masako Mori; Carolina A Yoshida; Chizuru Ito; Kenji Yamatoya; Takeshi Moriishi; Yosuke Kawai; Hisato Komori; Tetsuya Kawane; Shin-ichi Izumi; Kiyotaka Toshimori; Toshihisa Komori
Journal:  Histochem Cell Biol       Date:  2012-09-28       Impact factor: 4.304

3.  Genetic rescue of glycosylation-deficient Fgf23 in the Galnt3 knockout mouse.

Authors:  Shoji Ichikawa; Amie K Gray; Leah R Padgett; Matthew R Allen; Erica L Clinkenbeard; Nicole M Sarpa; Kenneth E White; Michael J Econs
Journal:  Endocrinology       Date:  2014-07-22       Impact factor: 4.736

4.  Nicotinamide treatment in a murine model of familial tumoral calcinosis reduces serum Fgf23 and raises heart calcium.

Authors:  Austin M Reilly; Amie K Gray; Sharon M Moe; Shoji Ichikawa
Journal:  Bone       Date:  2014-07-04       Impact factor: 4.398

Review 5.  Impact of the environment on the skeleton: is it modulated by genetic factors?

Authors:  Cheryl L Ackert-Bicknell; David Karasik
Journal:  Curr Osteoporos Rep       Date:  2013-09       Impact factor: 5.096

6.  Restriction of Dietary Phosphate Ameliorates Skeletal Abnormalities in a Mouse Model for Craniometaphyseal Dysplasia.

Authors:  Yasuyuki Fujii; Eszter Kozak; Eliane Dutra; Andras Varadi; Ernst J Reichenberger; I-Ping Chen
Journal:  J Bone Miner Res       Date:  2020-07-12       Impact factor: 6.390

Review 7.  Simultaneous management of disordered phosphate and iron homeostasis to correct fibroblast growth factor 23 and associated outcomes in chronic kidney disease.

Authors:  Guillaume Courbon; Marta Martinez-Calle; Valentin David
Journal:  Curr Opin Nephrol Hypertens       Date:  2020-07       Impact factor: 3.416

Review 8.  Hyperphosphatemic Tumoral Calcinosis: Pathogenesis, Clinical Presentation, and Challenges in Management.

Authors:  Alison M Boyce; Alisa E Lee; Kelly L Roszko; Rachel I Gafni
Journal:  Front Endocrinol (Lausanne)       Date:  2020-05-08       Impact factor: 5.555

9.  Inorganic Phosphate as a Novel Signaling Molecule with Antiproliferative Action in MDA-MB-231 Breast Cancer Cells.

Authors:  Annamaria Spina; Luigi Sapio; Antonietta Esposito; Francesca Di Maiolo; Luca Sorvillo; Silvio Naviglio
Journal:  Biores Open Access       Date:  2013-02

10.  A mouse with an N-Ethyl-N-nitrosourea (ENU) Induced Trp589Arg Galnt3 mutation represents a model for hyperphosphataemic familial tumoural calcinosis.

Authors:  Christopher T Esapa; Rosie A Head; Jeshmi Jeyabalan; Holly Evans; Tertius A Hough; Michael T Cheeseman; Eugene G McNally; Andrew J Carr; Gethin P Thomas; Matthew A Brown; Peter I Croucher; Steve D M Brown; Roger D Cox; Rajesh V Thakker
Journal:  PLoS One       Date:  2012-08-13       Impact factor: 3.240

  10 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.